ArticleThe Journal of experimental medicine1999
Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo.
Article in The Journal of experimental medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 153 citations in OpenAlex.
- Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.The Journal of clinical investigation · 2003Trial
- Atheroma transcriptomics identifies ARNTL as a smooth muscle cell regulator and with clinical and genetic data improves risk stratification.European heart journal · 2025Article
- Diagnostic value of Doppler ultrasound parameters combined with MMP-11 in early breast cancer and benign breast diseases.Oncology letters · 2020Article
- Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases.Saudi journal of biological sciences · 2019Article
- Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3.Cardiovascular engineering and technology · 2018Article
- CD40L and Its Receptors in Atherothrombosis-An Update.Frontiers in cardiovascular medicine · 2017Review
- Effect of cyclosporin A intervention on the immunological mechanisms of coronary heart disease and restenosis.Experimental and therapeutic medicine · 2016Article
- Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability.Journal of vascular research · 2016Review
- CD40-TRAF Signaling Upregulates CX3CL1 and TNF-α in Human Aortic Endothelial Cells but Not in Retinal Endothelial Cells.PloS one · 2015Article
- Functional relationship between matrix metalloproteinase-11 and matrix metalloproteinase-14.Cancer medicine · 2014Article
- Clinical study of the hypothesis of endogenous collateral wind on acute coronary syndrome: a review.African journal of traditional, complementary, and alternative medicines : AJTCAM · 2014Review
- Metalloproteinases and their natural inhibitors in inflammation and immunity.Nature reviews. Immunology · 2013Review
- The role of matrix metalloproteinases in atherothrombosis.Current atherosclerosis reports · 2011Review
- Tissue-dependent induction of apoptosis by matrix metalloproteinase stromelysin-3 during amphibian metamorphosis.Birth defects research. Part C, Embryo today : reviews · 2010Review
- Macrophage heterogeneity in atherosclerotic plaques.Current opinion in lipidology · 2009Review
- Quantum dot mediated imaging of atherosclerosis.Nanotechnology · 2009Article
- Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis.Atherosclerosis · 2008Article
- Regulation of extracellular matrix remodeling and cell fate determination by matrix metalloproteinase stromelysin-3 during thyroid hormone-dependent post-embryonic development.Pharmacology & therapeutics · 2007Review
- A microarray study of gene and protein regulation in human and rat brain following middle cerebral artery occlusion.BMC neuroscience · 2007Article
- The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats.Molecular and cellular biochemistry · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Stromelysin-3 is an unusual matrix metalloproteinase, being released in the active rather than zymogen form and having a distinct substrate specificity, targeting serine proteinase inhibitors (serpins), which regulate cellular functions involved in atherosclerosis. We report here that human atherosclerotic plaques (n = 7) express stromelysin-3 in situ, whereas fatty streaks (n = 5) and normal arterial specimens (n = 5) contain little or no stromelysin-3. Stromelysin-3 mRNA and protein colocalized with endothelial cells, smooth muscle cells, and macrophages within the lesion. In vitro, usual inducers of matrix metalloproteinases such as interleukin-1, interferon-gamma, or tumor necrosis factor alpha did not augment stromelysin-3 in vascular wall cells. However, T cell-derived as well as recombinant CD40 ligand (CD40L, CD154), an inflammatory mediator recently localized in atheroma, induced de novo synthesis of stromelysin-3. In addition, stromelysin-3 mRNA and protein colocalized with CD40L and CD40 within atheroma. In accordance with the in situ and in vitro data obtained with human material, interruption of the CD40-CD40L signaling pathway in low density lipoprotein receptor-deficient hyperlipidemic mice substantially decreased expression of the enzyme within atherosclerotic plaques. These observations establish the expression of the unusual matrix metalloproteinase stromelysin-3 in human atherosclerotic lesions and implicate CD40-CD40L signaling in its regulation, thus providing a possible new pathway that triggers complications within atherosclerotic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.